GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance
Chronic Diseases and Translational Medicine · 2026
DOI: 10.1002/cdt3.70059 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chronic Diseases and Translational Medicine, 2026. Verfasst von Junaid Beig und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology Royal Hobart Hospital Hobart Tasmania Australia. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients undergoing gastrointestinal endoscopy. Although GLP‐1RAs provide significant metabolic, cardiovascular, and hepatic benefits, their tendency to slow gastric emptying has raised concerns about retained gastric contents (RGC), procedural complications, and a greater risk of pulmonary aspiration during sedation or anesthesia. This review offers a translational narrative synthesis of mechanistic, physiological, and clinical evidence connecting GLP‐1RA therapy to changes in gastric motility and peri‐endoscopic outcomes. Data from pharmacological studies, scintigraphic evaluations, large observational cohorts, and international consensus statements are combined to guide physiology‐based procedural decisions. Evidence consistently indicates that GLP‐1RA exposure is associated with a higher incidence of RGC and more frequent procedural disruptions during upper gastrointestinal endoscopy. However, it remains uncertain whether RGC leads to clinically significant aspiration. Consistent with this, real‐world data reveal no increase in aspiration pneumonia among GLP‐1RA users undergoing colonoscopy, with reported aspiration rates of approximately 0.01%–0.05%. Likewise, during upper gastrointestinal endoscopy, only a small absolute rise in aspiration‐related events has been observed, involving fewer than 0.3% of procedures. Current guidelines favor continuing GLP‐1RA therapy alongside dietary modification, structured risk assessment, selective gastric point‐of‐care ultrasound (POCUS), and multidisciplinary communication, rather than routine cessation. Emerging prospective evidence indicates that implementing a pre‐procedural clear liquid diet, with individualized timing of weekly agents, may reduce the risk of clinically significant RGC, complementing existing dietary preparation strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology Royal Hobart Hospital Hobart Tasmania Australia.
- Department of Anaesthesiology and Critical Care Sher-i-Kashmir Institute of Medical Sciences, Soura Srinagar Jammu and Kashmir India.
- General Surgery, Wyong Hospital Central Coast Local Health District Hamlyn terrace New South Wales Australia.
- Department of Anaesthesia Royal Hobart Hospital Hobart Tasmania Australia.
ORCID-Profile: Junaid Beig, Jason Ta, Puneet Chhabra
Zitieren
APA
Beig, J., Ta, J., Jones, S., Scott, E., Sofi, K., Osler, F., Jansen, M., & Chhabra, P. (2026). GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance. Chronic Diseases and Translational Medicine. https://doi.org/10.1002/cdt3.70059
Vancouver
Beig J, Ta J, Jones S, Scott E, Sofi K, Osler F, et al. GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance. Chronic Diseases and Translational Medicine. 2026. doi:10.1002/cdt3.70059
BibTeX
@article{Beig2026,
author = {Beig, Junaid and Ta, Jason and Jones, Sophie and Scott, Emily and Sofi, Khalid and Osler, Frances and Jansen, Marije and Chhabra, Puneet},
title = {GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance},
journal = {Chronic Diseases and Translational Medicine},
year = {2026},
doi = {10.1002/cdt3.70059}
}
EUVIMED